NASDAQ · WOK

WORK Medical Technology Group Ltd.

$2.04 +$0.16 (+8.51%) 1D After hours

Key Metrics

$4.54M
Market cap
P/E · TTM
Revenue · TTM
−$1.07M
Net income
EPS · TTM $-0.09
Dividend yield
Free cash flow $4.91M
Beta · 1Y 1.21
EBITDA · TTM −$233.31K
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 21
    From its May 12 high, the share price fell 100%.

    Peak close $666.00 on May 12; trough close $1.87 on Jul 21. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -100%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 12
    The stock moved +69.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 12
  • May 11
    The stock moved +206.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 11

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$4.54M
Enterprise value
Shares outstanding2.4M
52-wk range$0.05 – $733.00
Avg volume · 20D2.5M
Net cash
Book value / share$1.47
ExchangeNASDAQ
About WORK Medical Technology Group Ltd.
IPO dateAug 23, 2024
Employees238

WORK Medical Technology Group Ltd is engaged in manufacturing and selling medical consumables through its wholly owned subsidiaries in the People's Republic of China.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF0.93
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -6.8% · -8.4%

Financial Health

Current ratio1.71
Quick ratio1.50
Debt / equity
Debt / EBITDA
Net cash
Working capital$8.48M

Cash Flow · TTM

Operating CF $6.24M
Capex −$1.33M
Free cash flow $4.91M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-03-31 · computed by TickerWolf from SEC filings